Protective proteins of
The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae ( S. agalactiae ) or functionally active variant thereof; a protective peptide against S. agalactiae ; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S. agalactiae infection; a method for identifying a ligand capable of binding the composition and/or at least one protective peptide; and the use of the composition and/or at least one protective peptide for the isolation and/or purification and/or identification of an interaction partner of the composition and/or peptide.
1. A composition comprising a first protective protein and a second protective protein,
i) wherein the first protective protein consists of the amino acid sequence of SEQ ID NO: 5 (gbs1478p) or functionally active protein that consists of at least 95% identity to the sequence of SEQ ID NO:5; and
wherein the functionally active protein shows at least 80% of the protection shown for the protective protein of SEQ ID NO: 5 against challenge with at least one strain of S. agalactiae used in a dose of 10 6 -10 8 cfu in a lethal sepsis model, wherein the strain is selected from the group consisting of C388/90, A909, ATCC12401, ATCC1243, COH1, BAA22, BAA23, 2603V/R, and ATCC49447;
ii) wherein the second protective protein consists of the amino acid sequence of SEQ ID NO: 6 (gbs2018p) or functionally active protein that consists of at least 95% identity to the sequence of SEQ ID NO: 6; and
wherein the functionally active protein shows at least 80% of the protection shown for the protective protein of SEQ ID NO: 6 against challenge with at least one strain of S. agalactiae used in a dose of 10 6 -10 8 cfu in a lethal sepsis model, wherein the strain is selected from the group consisting of C388/90, A909, ATCC12401, ATCC1243, COH1, BAA22, BAA23, 2603V/R, and ATCC49447.
2. The composition of claim 1 , wherein the first protective protein consists of the amino acid sequence of SEQ ID NO: 5 (gbs1478p).
3. The composition of claim 1 , wherein the second protective protein consists of the amino acid sequence of SEQ ID NO: 6 (gbs2018p).
4. The composition of claim 1 , wherein
i) the first protective protein consists of the amino acid sequence of SEQ ID NO: 5 gbs1478p); and
ii) the second protective protein consists of the amino acid sequence of SEQ ID NO: 6 (gbs2018p).
5. The composition of claim 1 , wherein the first protective protein and the second protective protein are combined into at least one fusion protein.
6. A pharmaceutical composition comprising
(i) the composition according to claim 1 ; and
(ii) optionally a pharmaceutically acceptable carrier or excipient.
7. The pharmaceutical composition of claim 6 , further comprising an immunostimulatory substance.
8. The pharmaceutical composition of claim 7 , wherein the immunostimulatory substance is an adjuvant.
9. A pharmaceutical composition comprising
(i) the composition according to claim 2 ; and
(ii) optionally a pharmaceutically acceptable carrier or excipient.
10. The pharmaceutical composition of claim 9 , further comprising an immunostimulatory substance.
11. The pharmaceutical composition of claim 10 , wherein the immunostimulatory substance is an adjuvant.
12. A method of inducing an immune response in a subject against S. agalactiae infection comprising administering an effective amount of the composition of claim 1 to said subject.